National organizations that represent patients with multiple sclerosis (MS) welcome the U.S. Food and Drug Administration’s March 26 approval of Novartis’ oral therapy Mayzent (siponimod) — but they complain that, at $88,500 per ... Read more
Treatment of secondary progressive multiple sclerosis (SPMS) patients with the investigational oral therapy Mayzent (siponimod) significantly reduced the risk of disability progression and decreased inflammation, compared to best supportive ... Read more
Restrictive access policies by Medicare and a rising cost-sharing burden lead to an increased price of disease-modifying therapies for multiple sclerosis patients, according to new research.
The findings also revealed ... Read more
People with multiple sclerosis (MS) who quit smoking have better health outcomes than those who continue. Therefore, MS-related costs can be reduced by encouraging smokers to quit. Similar results were observed ... Read more
Ocrevus is a less expensive treatment option for relapsing multiple sclerosis than Rebif in the long-run, according to a cost-effectiveness analysis published in the Journal of Medical Economics.
In addition ... Read more
The burden of moderate-to-severe relapses in multiple sclerosis (MS) patients is underappreciated, according to a study sponsored by the pharmaceutical company Mallinckrodt. Researchers discussed the findings at the American Academy ... Read more
Clinical results presented at the recent Academy of Managed Care Pharmacy (AMCP)‘s 2016 annual meeting in San Francisco showed that the use of H.P. Acthar Gel during multiple sclerosis (MS) relapses ... Read more